Funding Requirements Lead To ‘Difficult Trade-offs’ Between HIV Prevention, Treatment Efforts

The Hill: HIV in 2016: do we vaccinate now or pay more to treat later?
Jason Reed, epidemiologist and senior technical adviser with Jhpiego

“…To reach [the goal of an AIDS-free generation] … both approaches — primary prevention to protect uninfected people and drugs to treat those already HIV-infected — must be used simultaneously, without delay and almost universally. The Catch-22? There currently isn’t enough money to pay for both approaches at the levels required, leading to difficult trade-offs. … [For instance, the] current PEPFAR leadership has shuttered countless circumcision clinics in a rush to abide by extant U.S. congressional funding ‘earmarks’ for treatment. … If preventing HIV through male circumcision — the single most cost-effective HIV prevention strategy for the hardest hit countries — is too expensive, how can immediate and lifelong treatment for all HIV-positive people be anything but impossible? Either both prevention and treatment options are possible — an epidemiologically sound formula for balancing ounces of prevention and pounds of care — or the end of AIDS will be indefinitely postponed” (5/12).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.